We develop new
treatments for central
nervous system disorders.

We develop new
treatments for central
nervous system disorders.

Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Latest News

  • Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?

  • For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.

  • At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.

  • We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.

Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics

January 11, 2023
– Study data shows investigational new drug, ecopipam, reduced total number of tics by 30% compared to placebo –  CHICAGO—January 11, 2023 – A Phase 2b clinical trial involving more than 150 children and adolescents with Tourette syndrome found ecopipam significantly reduced the total number of ... Read more
Read More →

Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome

November 3, 2022
– Clinical stage biopharmaceutical company completes upsized, oversubscribed Series D financing from leading life sciences investors –  CHICAGO—November 3, 2022 – Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial ... Read more
Read More →

Emalex Biosciences to Present Positive Results for Pediatric Tourette Syndrome Study at AAN Annual Meeting

March 31, 2022
– Findings show investigational drug reduces tics by 30%; Data presentation April 5 –  Chicago, March 31, 2022 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company focused on developing treatments for central nervous system (CNS) movement disorders and fluency disorders, will present an abstract — ... Read more
Read More →

Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Latest News

  • Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?

  • For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.

  • At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.

  • We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.

First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy

By emalexadmin | March 9, 2026
Study opens pathway to investigational therapy for patients with Tourette syndrome who have exhausted approved treatments CHICAGO — March 9, 2026 — Emalex Biosciences today announced that the first patient was dosed in its Expanded Access Program for ecopipam, an investigational first-in-class D1 receptor antagonist ... Read more
Read More →

Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?

For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.

At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.

We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.

First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy

By emalexadmin | March 9, 2026
Study opens pathway to investigational therapy for patients with Tourette syndrome who have exhausted approved treatments CHICAGO — March 9, 2026 — Emalex Biosciences today announced that the first patient was dosed in its Expanded Access Program for ecopipam, an investigational first-in-class D1 receptor antagonist ... Read more
Read More →

Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Drug Receives FDA Authorization

By emalexadmin | October 8, 2025
Chicago biotech focused on CNS disorders to submit New Drug Application in December for first-in-class treatment CHICAGO — October 8, 2025 — Emalex Biosciences today announced that the U.S. Food and Drug Administration has authorized the company’s Expanded Access Program (EAP) for ecopipam, an investigational ... Read more
Read More →